AGEN AGENUS INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1098972 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY25.4%
TTM net income YoY187.7%
TTM EPS YoY114.6%
Revenue 3-yr CAGR9.9%
Net income 3-yr CAGR—
Margins
Gross margin100.0%
Operating margin38.9%
Net margin23.0%
FCF margin-77.5%
EBITDA margin40.6%
Returns
ROE—
ROA12.9%
ROIC (approx.)—
Asset turnover0.56x
Leverage & solvency
Liabilities / assets145.7%
Debt / equity—
Current ratio0.73x
Interest coverage0.85x
Cash quality & payout
Operating cash flow / net income-3.37x
Accruals ratio56.2%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $31.49M | $34.52M | $33.74M | $34.20M | $30.23M | $25.69M | $24.07M | $26.84M |
| Cost of revenue | $0 | $0 | $0 | $0 | $642,000 | $243,000 | $137,000 | $118,000 |
| Gross profit | $31.49M | $34.52M | $33.74M | $34.20M | $29.59M | $25.45M | $23.93M | $26.72M |
| R&D expense | $11.65M | $14.76M | $11.82M | $7.51M | $23.60M | $26.71M | $21.52M | $33.77M |
| SG&A expense | $8.43M | $8.47M | $6.86M | $12.29M | $10.86M | $15.52M | $15.72M | $20.93M |
| Operating income | $11.41M | $11.29M | $15.05M | $14.40M | -$4.54M | -$16.71M | -$13.31M | -$25.90M |
| Interest expense | $14.93M | $15.36M | $14.69M | $16.05M | $13.24M | $13.34M | $12.98M | $21.11M |
| Net income | $2.73M | -$550,000 | $39.23M | -$10.58M | $63.91M | -$27.95M | -$25.27M | -$45.86M |
| EBITDA | $11.92M | $11.81M | $15.64M | $14.99M | -$1.51M | -$13.54M | -$10.11M | -$22.64M |
| EPS (basic) | 0.02 | -0.01 | 1.03 | — | 2.00 | -1.00 | -1.03 | — |
| EPS (diluted) | 0.02 | -0.01 | 1.02 | — | 1.94 | -1.00 | -1.03 | — |
| Weighted avg. shares (diluted) | 83.27M | 41.34M | 38.28M | — | 32.86M | 28.12M | 24.47M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $66.94M | $18.74M | $35.00M | $3.00M | $3.46M | $9.53M | $18.49M | $40.44M |
| Short-term investments | $20.00M | — | — | $0 | — | — | — | — |
| Receivables | $17.08M | $14.72M | $6.56M | $1.83M | $538,000 | $709,000 | $354,000 | $407,000 |
| Current assets | $148.31M | $78.81M | $95.28M | $133.44M | $133.95M | $13.34M | $23.14M | $45.57M |
| PP&E, net | $13.89M | $14.32M | $14.95M | $15.47M | $15.99M | $112.72M | $117.03M | $120.09M |
| Goodwill | $24.09M | $24.09M | $24.09M | $24.09M | $24.09M | $24.09M | $24.09M | $24.09M |
| Intangibles | $2.80M | $2.88M | $2.96M | $3.04M | $3.12M | $3.21M | $3.29M | $3.38M |
| Total assets | $245.55M | $172.69M | $186.46M | $226.80M | $233.89M | $185.22M | $200.20M | $226.27M |
| Current liabilities | $203.69M | $231.82M | $249.24M | $323.49M | $287.13M | $234.56M | $208.30M | $221.40M |
| Short-term debt | $5.35M | $30.07M | $30.19M | $44.66M | $10.61M | $10.72M | $731,000 | $2.70M |
| Long-term debt | $24.43M | $30.07M | $30.19M | $0 | $23.60M | $23.15M | $32.85M | $30.47M |
| Total debt | $29.78M | $60.14M | $60.39M | $44.66M | $34.21M | $33.87M | $33.58M | $33.17M |
| Total liabilities | $357.70M | $378.54M | $414.44M | $504.66M | $514.76M | $521.53M | $522.60M | $532.70M |
| Shareholders' equity | -$105.37M | -$199.07M | -$221.22M | -$271.11M | -$274.14M | -$354.60M | -$341.85M | -$326.38M |
| Net debt | -$37.15M | $41.40M | $25.39M | $41.66M | $30.75M | $24.34M | $15.09M | -$7.27M |
| Shares outstanding | 45.21M | 42.62M | 38.52M | 35.32M | 32.81M | 30.00M | 26.56M | 23.63M |
| Cash flow statement | ||||||||
| Operating cash flow | -$20.09M | -$31.20M | -$35.95M | -$16.62M | -$14.74M | -$20.22M | -$25.62M | -$28.65M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 | $1,000 | $5,000 | $73,000 |
| Free cash flow | -$20.09M | -$31.20M | -$35.95M | -$16.62M | -$14.74M | -$20.22M | -$25.62M | -$28.73M |
| Investing cash flow | -$19.88M | $267,000 | $68.95M | $780,000 | $76,000 | $281,000 | $57,000 | -$21,000 |
| Financing cash flow | $87.56M | $14.68M | -$993,000 | $15.37M | $6.68M | $10.94M | $3.59M | $24.37M |
| Depreciation & amortization | $513,000 | $517,000 | $583,000 | $597,000 | $3.03M | $3.17M | $3.20M | $3.26M |
| Stock-based compensation | $2.92M | $3.26M | $1.10M | $3.46M | $2.81M | $3.44M | $3.48M | $4.67M |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.